Citations

Institution: Mayo Clinic Clear

Showing 10 of 108135 citations.

Synergistic effect of teclistamab with PD-1 inhibition: a case of acute interstitial nephritis with dual immunotherapy
Mohan, Arjunmohan , Barbir, Elena-Bianca , Hernandez, Loren Herrera, Leung, Nelson , Herrmann, Sandra M. , Leung, Nelson , Herrmann, Sandra M

Clinical Kidney Journal | December 21, 2024 | Volume: 18 | Issue: 2 | Pages: No page available

10.1093/ckj/sfae425 | PMID 39974847 Get It

ABSTRACT We report a case of acute interstitial nephritis (AIN) in a 68-year-old male with squamous cell carcinoma (SCC) and relapsed/refractory multiple myeloma (RRMM) who developed acute kidney injury (AKI) shortly after starting teclistamab for RRMM. Despite stable renal function on immune checkpoint inhibitor (ICI) therapy for SCC, proton pump inhibitors and trimethoprim-sulfamethoxazole for 3 years, AKI only occurred post-teclistamab initiation. Biopsy-confirmed AIN with serum creatinine improved only after pulse-dose steroids. This case highlights a potential synergistic nephrotoxic effect of teclistamab and ICIs, warranting further investigation into teclistamab's renal safety.
Paths cross and diverge: unique perioperative risk factors of persistent postoperative opioid use versus chronic postsurgical pain – an infographic
D’Souza, Ryan S. , Labandeyra, Hipólito , D'Souza, Ryan S

Regional Anesthesia & Pain Medicine | December 21, 2024 | Volume: 51 | Issue: 3 | Pages: 360-360

10.1136/rapm-2024-106281 | PMID 39709190 Get It

The association of statin therapy with reduced intracranial aneurysm recurrence after endovascular coiling: a post hoc propensity score–matched analysis of a randomized clinical trial
Patra, Devi P. , Abi-Aad, Karl R., Turcotte, Evelyn L. , Ogilvy, Christopher S., Siddiqui, Adnan H. , Veznedaroglu, Erol, Batjer, H. Hunt , Bendok, Bernard R. , Ogilvy, Christopher S. , Siddiqui, Adnan H , Ogilvy, Christopher S , Levy, Elad I.

Journal of Neurosurgery | December 20, 2024 | Volume: 142 | Issue: 5 | Pages: 1366-1375

10.3171/2024.7.jns24781 | PMID 39705700 Get It

OBJECTIVE Endovascular intracranial aneurysm (IA) management has significantly evolved over the last 2 decades. Despite these advancements, the aneurysm recanalization rate after coil embolization remains a concern. Statins have been found to affect vascular repair and remodeling; therefore, the authors hypothesized that patients receiving statin therapy at the time of coil embolization would have lower aneurysm recurrence and retreatment rates compared with patients not receiving statin therapy. METHODS A post hoc analysis was conducted of the primary data from patients enrolled in the Hydrogel Endovascular Aneurysm Treatment Trial focusing on the impact of statin use on the recurrence rates of 3- to 14-mm IAs after endovascular coiling. The primary outcome measured included aneurysm recurrence over 18–24 months using the Raymond-Roy Occlusion Classification. Secondary outcomes included major and minor recurrence rates and retreatment rates. Propensity score matching based on patient and aneurysm characteristics was performed to mitigate selection bias. RESULTS A total of 577 patients with data on statin use were eligible for this analysis. Of these, 178 (30.8%) patients were using statins and 399 (69.2%) were not. After propensity score matching, 156 (39.2%) patients were included in the statin group and 242 (60.8%) in the nonstatin group. The recurrence rate was 3.8% (6/156) in the statin group and 10.7% (26/242) in the nonstatin group (p = 0.013). In a subgroup analysis, statin use significantly reduced recurrence in patients with unruptured aneurysms (1.6% vs 9.7%, p = 0.005), but not in those with ruptured aneurysms (12.5% vs 13.6%, p = 0.876). CONCLUSIONS Statin use was associated with a reduced rate of aneurysm recurrence in patients who underwent endovascular coiling for IAs with a decreased rate of retreatment during the follow-up period. Statins are a relatively low-risk treatment and may be an effective therapy to reduce recanalization of IAs, although further prospective studies are warranted to validate these findings.
Executive Summary of State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
Yetmar, Zachary A. , Marty, Paige K. , Clement, Josh , Miranda, Cyndee , Wengenack, Nancy L. , Beam, Elena , Yetmar, Zachary A , Beam, Elena

Clinical Infectious Diseases | December 20, 2024 | Volume: 80 | Issue: 4 | Pages: 701-702

10.1093/cid/ciae644 | PMID 40305687 Get It

Integrating Artificial Open Generative Artificial Intelligence into Software Supply Chain Security
Alevizos, Vasileios , Simasiku, Akebu, Malliarou, Dimitra, Edralin, Sabrina , Xu, Clark , Yue, Zongliang , Papakostas, George A. , Messinis, Antonis, Yue, Zongliang , Edralin, Sabrina , Xu, Clark

2024 5th International Conference on Data Analytics for Business and Industry (ICDABI) | December 20, 2024 | Volume: No volume available | Issue: No issue available | Pages: 200-206

10.1109/icdabi63787.2024.10800301 Get It

Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration
Sandahl, Tyler B. , Soefje, Scott A. , Ailawadhi, Sikander , Parrondo, Ricardo , Lin, Dee , Wu, Bingcao , Calay, Ediz S. , Silvert, Eli , Carpenter, Corinne , Wagner, Tyler E. , Fowler, Jessica , Hester, Laura , Rangarajan, Nivedita , Marshall, Alexander Mclean, Stoy, Patrick, Gifkins, Dina , Kumar, Shaji , Ailawadhi, Sikander , Parrondo, Ricardo D , Lin, Dee , Wu, Bingcao , Calay, Ediz S , Wagner, Tyler E , Hester, Laura , Murugadoss, Karthik , Gifkins, Dina , Lin, Yi , Kumar, Shaji K , Soefje, Scott A , Sandahl, Tyler B , Fonseca, Rafaël , Kim, Nina , Fowler, Jessica, Murugadoss, Karthik , Marshall, Alexander, Lin, Yi

JCO Oncology Practice | December 20, 2024 | Volume: 21 | Issue: 5 | Pages: 702-709

10.1200/op-24-00489 | PMID 39705632 Get It

PURPOSE Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital setting. This study aimed to evaluate safety and health care resource utilization (HRU) in real-world patients with multiple myeloma who initiated teclistamab SUD in an outpatient setting. METHODS This was a retrospective study using Mayo Clinic's electronic medical records from October 26, 2022, to October 31, 2023. Patient characteristics were summarized for all patients treated with teclistamab and separately for patients who started SUD outpatient. SUD pattern, safety, HRU, and post-SUD dosing schedule were described in patients with complete SUD. RESULTS At data cutoff, 65 patients received ≥1 teclistamab dose, including 58 patients who initiated SUD outpatient (median age, 69.2 years; male, 63.8%; White, 89.7%). Among 57 patients who completed SUD in an outpatient setting, all received premedications on the days of teclistamab administrations per label recommendation; 18 (31.6%) developed CRS (13 grade 1, four grade 2, and one grade 4) and two developed ICANS (one each with grade 2 and 4). All CRS and ICANS resolved with supportive care and all patients continued treatment. Eighteen patients were admitted to the hospital for CRS treatment, with a median CRS-related hospital stay of 2 days per admission. Most (60%) doses during SUD required <1 hour clinic time between administration and checkout. Post-SUD, clinic time for treatment doses decreased to <30 minutes for most doses (82%). CONCLUSION Outcomes of this study support outpatient administration as a safe and feasible option for teclistamab SUD to potentially reduce HRU and improve patient experiences.
State-of-the-Art Review: Modern Approach to Nocardiosis—Diagnosis, Management, and Uncertainties
Yetmar, Zachary A. , Marty, Paige K. , Clement, Josh , Miranda, Cyndee , Wengenack, Nancy L. , Beam, Elena , Yetmar, Zachary A , Beam, Elena

Clinical Infectious Diseases | December 20, 2024 | Volume: 80 | Issue: 4 | Pages: e53-e64

10.1093/cid/ciae643 | PMID 40305688 Get It

Abstract Nocardiosis is an uncommon yet potentially devastating infection. Nocardia tends to affect individuals with chronic lung disease or immunocompromising conditions, 2 groups increasing in number. Incidence of nocardiosis is likely to increase as well, and it is vital to have an approach to this complex disease. Here, we aim to review the presentation, diagnosis, and management of Nocardia in the modern era. We will also highlight areas of uncertainty in our understanding of nocardiosis and propose a general approach to nocardiosis therapy, accounting for response and tolerance of Nocardia treatment.
A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies
Davids, Matthew S. , Brander, Danielle M. , Alvarado, Yesid , Egan, Daniel Nathan, Dinner, Shira, Malki, Monzr M. Al , Begna, Kebede H. , Bhatt, Vijaya Raj , Abedin, Sameem , Cook, Rachel J. , Collins, Mary C. , Roleder, Carly , Rajagopalan, Prabhu , Danilov, Alexey V., Alvarado-Valero, Yesid , Diefenbach, Catherine S , Egan, Daniel N , Dinner, Shira N , Javidi-Sharifi, Nathalie , Al Malki, Monzr M , Begna, Kebede , Bhatt, Vijaya Raj , Abedin, Sameem , Cook, Rachel J , Collins, Mary C , Roleder, Carly , Dominguez, Edward C , Rajagopalan, Prabhu , Wiley, Sandra E , Ghalie, Richard G , Danilov, Alexey V , Davids, Matthew S , Diefenbach, Catherine , Egan, Daniel

Blood Advances | December 20, 2024 | Volume: 9 | Issue: 4 | Pages: 820-832

10.1182/bloodadvances.2024014633 | PMID 39705540 Get It

Abstract The antiapoptotic protein, myeloid cell leukemia-1 (Mcl-1), contributes to the pathophysiology of acute myeloid leukemia (AML) and certain B-cell malignancies. Tumor dependence on Mcl-1 is associated with resistance to venetoclax. Voruciclib, an oral cyclin-dependent kinase (CDK) inhibitor targeting CDK9, indirectly decreases Mcl-1 protein expression and synergizes with venetoclax in preclinical models. This dose escalation study evaluated voruciclib in patients with previously treated hematologic malignancies. Initially, voruciclib was administered daily, continuously, on a 28-day cycle (group 1). After 2 patients with prior allogeneic stem cell transplantation had a dose-limiting toxicity (DLT) of interstitial pneumonitis at 100 mg, voruciclib administration was changed to days 1 to 14 of a 28-day cycle (group 2). Forty patients, 21 with AML and 19 with B-cell malignancies, were enrolled. Patients had a median of 3 prior lines of therapy (range, 1-8). Dose escalation in group 2 was stopped at 200 mg, a dose that achieved plasma concentrations sufficient for target inhibition, without DLTs observed. The most common adverse events were diarrhea (30%), nausea (25%), anemia (22%), fatigue (22%), constipation (17%), dizziness (15%), and dyspnea (15%). In AML, 1 patient achieved a morphologic leukemia-free state, and 2 had stable disease. Voruciclib treatment led to a decrease in MCL1 messenger RNA expression, downregulation of myelocytomatosis (MYC) and NF-κB transcriptional gene sets, and reduced phosphorylation of RNA polymerase 2. Voruciclib on intermittent dosing was well tolerated, with no DLTs, paving the way for evaluation of the combination of voruciclib with venetoclax for patients with previously treated AML. This trial was registered at www.clinicaltrials.gov as #NCT03547115.
Improving Ovarian Cancer Detection: Can CEUS Refine the O-RADS System?
Baumgarten, Deborah A.

Radiology: Imaging Cancer | December 20, 2024 | Volume: 7 | Issue: 1 | Pages: No page available

10.1148/rycan.240397 | PMID 39704668 Get It

Prospective Noninvasive Hemoglobin Monitoring in the Outpatient Total Joint Arthroplasty Setting
Dugdale, Evan M. , Mallinger, Benjamin D, Bedard, Nicholas A. , Couch, Cory , Mabry, Tad M. , Perry, Kevin I. , Sierra, Rafael J. , Taunton, Michael J. , Trousdale, Robert T. , Abdel, Matthew P. , Couch, Cory C , Abdel, Matthew P , Sierra, Rafael J , Taunton, Michael J , Bedard, Nicholas A , Mallinger, Benjamin D , Perry, Kevin I.

Journal of Bone and Joint Surgery | December 20, 2024 | Volume: 107 | Issue: 4 | Pages: 364-371

10.2106/jbjs.24.00438 | PMID 39705371 Get It

Background: Total joint arthroplasty (TJA) is increasingly being performed as an outpatient (i.e., same-day discharge) procedure. Postoperatively, orthostatic hypotension or pain-related tachycardia can lead to concerns regarding the hemoglobin (Hgb) level of the patient prior to discharge. The purpose of this study was to prospectively assess the reliability and accuracy of, and patient and nurse satisfaction with, postoperative noninvasive hemoglobin (nHgb) monitoring compared with an invasive serum hemoglobin (iHgb) laboratory draw in the outpatient TJA setting. Methods: We prospectively enrolled 200 patients undergoing outpatient unilateral TJA, of whom 157 were ultimately included in our analysis (94 hips, 63 knees). Postoperatively, both nHgb and iHgb values were obtained at a mean of 36 minutes apart. Surveys were completed by patients and nurses. The strength of the agreement between the 2 Hgb monitoring methods was evaluated with use of the Bland-Altman 95% limits of agreement, concordance correlation coefficient (CCC), and intraclass correlation coefficient (ICC). Receiver operating characteristic curve analyses were performed to investigate the ability of nHgb monitoring to predict an iHgb of <11.2 g/dL (the 5th-percentile iHgb value). Results: The mean preoperative iHgb was 14.2 ± 1.1 g/dL. The mean postoperative iHgb and nHgb values were 13.3 ± 1.5 and 13.3 ± 1.2 g/dL, respectively. The Bland-Altman 95% limits of agreement were −3.2 and +3.1 g/dL, indicating that 95% of patients’ iHgb values are expected to fall between these limits relative to the nHgb value of the patient. The CCC and ICC were both 0.33. An nHgb cutoff value of <12.7 g/dL had 100% sensitivity and 67% specificity for detecting an iHgb of <11.2 g/dL. Patients reported less pain with the nHgb test than with the iHgb test (mean pain score, 0.0 versus 1.8; p < 0.001), and 97% of patients preferred the nHgb test. Following the nHgb test, 73% of responding patients and 83% of responding nurses were “somewhat more reassured” to “significantly more reassured” about same-day discharge. Conclusions: Routine nHgb testing can rapidly screen patients undergoing outpatient TJA for acute anemia prior to discharge. With an nHgb of <12.7 g/dL, there was perfect sensitivity and 67% specificity for detecting an iHgb of <11.2 g/dL. Most patients and nurses felt more reassured about same-day discharge after nHgb monitoring. Level of Evidence: Diagnostic Level II . See Instructions for Authors for a complete description of levels of evidence.